Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells

Leukemia

Volumn 29, Issue 6, 2015, Pages 1267-1278

  Fiskus, W ^a   Sharma, S ^b   Saha, S ^a   Shah, B ^a   Devaraj, S G T ^a   Sun, B ^a   Horrigan, S ^c   Leveque, C ^a   Zu, Y ^a   Iyer, S ^a   Bhalla, K N ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c Beta Cat Pharmaceutical   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; BC 2059; BETA CATENIN; CARFILZOMIB; CYCLIN D1; FLT3 LIGAND; LYMPHOID ENHANCER FACTOR 1; MYC PROTEIN; PANOBINOSTAT; SURVIVIN; T CELL FACTOR 4; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW PROGENITOR CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; M PHASE CELL CYCLE CHECKPOINT; ONCOGENE C MYC; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SURVIVAL RATE; TRANSCRIPTION INITIATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; IMMUNOPRECIPITATION; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; IMMUNOPRECIPITATION; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, NUDE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930576441     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.340     Document Type: Article

References (57)

1. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012; 149: 1192-1205.
2. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z et al. The Wnt/ beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 327: 1650-1653.
3. Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D et al. beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010; 18: 606-618.
4. Lane SW, Wang YJ, Lo Celso C, Ragu C, Bullinger L, Sykes SM et al. Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood 2011; 118: 2849-2856.
5. Petropoulos K, Arseni N, Schessl C, Stadler CR, Rawat VP, Deshpande AJ et al. A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med 2008; 205: 515-522.
6. Niehrs C. The complex world of WNT receptor signaling. Nat Rev Mol Cell Biol 2012; 13: 767-779.
7. Li W, Hou Y, Ming M, Yu L, Seba A, Qian Z. Apc regulates the function of hematopoietic stem cells largely through beta-catenin-dependent mechanisms. Blood 2013; 121: 4063-4072.
8. Li VS, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP et al. Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell 2012; 149: 1245-1256.
9. Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol 2010; 6: 829-836.
10. Dimitrova YN, Li J, Lee YT, Rios-Esteves J, Friedman DB, Choi HJ et al. Direct ubiquitination of beta-catenin by Siah-1 and regulation by the exchange factor TBL1. J Biol Chem 2010; 285: 13507-13516.
11. Zhang N, Wei P, Gong A, Chiu WT, Lee HT, Colman H et al. FoxM1 promotes -catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 2011; 20: 427-442.
12. Xing Y, Takemaru K, Liu J, Berndt JD, Zheng JJ, Moon RT et al. Crystal structure of a full-length beta-catenin. Structure 2008; 16: 478-487.
13. Sampietro J, Dahlberg CL, Cho US, Hinds TR, Kimelman D, Xu W. Crystal structure of a beta-catenin/BCL9/Tcf4 complex. Mol Cell 2006; 24: 293-300.
14. Mo R, Chew TL, Maher MT, Bellipanni G, Weinberg ES, Gottardi CJ. The terminal region of beta-catenin promotes stability by shielding the Armadillo repeats from the axin-scaffold destruction complex. J Biol Chem 2009; 284: 28222-28231.
15. Mosimann C, Hausmann G, Basler K. Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol 2009; 10: 276-286.
16. Valencia A, Roman-Gomez J, Cervera J, Such E, Barragan E, Bolufer P et al. Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. Leukemia 2009; 23: 1658-1666.
17. Kajiguchi T, Chung EJ, Lee S, Stine A, Kiyoi H, Naoe T et al. FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells. Leukemia 2007; 21: 2476-2484.
18. Kajiguchi T, Katsumi A, Tanizaki R, Kiyoi H, Naoe T. Y654 of beta-catenin is essential for FLT3/ITD-related tyrosine phosphorylation and nuclear localization of beta-catenin. Eur J Haematol 2012; 88: 314-320.
19. Morgan RG, Pearn L, Liddiard K, Pumford SL, Burnett AK, Tonks A et al. -Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of -catenin. Leukemia 2013; 27: 336-343.
20. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. N Engl J Med 2004; 351: 657-667.
21. Coluccia AM, Vacca A, Dunach M, Mologni L, Redaelli S, Bustos VH et al. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 2007; 26: 1456-1466.
22. Jiang J, Griffin JD. Wnt/beta-catenin pathway modulates the sensitivity of the mutant FLT3 receptor kinase inhibitors in a GSK-3beta dependent manner. Genes Cancer 2010; 1: 164-176.
23. Perry JM, He XC, Sugimura R, Grindley JC, Haug JS, Ding S et al. Cooperation between both Wnt/{beta}-catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion. Genes Dev 2011; 25: 1928-1942.
24. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S et al. beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012; 18: 892-901.
25. Gehrke I, Gandhirajan RK, Kreuzer KA. Targeting the WNT/beta-catenin/TCF/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic options. Eur J Cancer 2009; 45: 2759-2767.
26. Minke KS, Staib P, Puetter A, Gehrke I, Gandhirajan RK, Schlosser A et al. Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur J Haematol 2009; 82: 165-175.
27. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13: 11-26.
28. Curtin JC, Lorenzi MV. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 2010; 1: 552-566.
29. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010; 16: 3153-3162.
30. Li J, Wang CY. TBL1-TBLR1 and beta-catenin recruit each other to Wnt target-gene promoter for transcription activation and oncogenesis. Nat Cell Biol 2008; 10: 160-169.
31. Choi HK, Choi KC, Yoo JY, Song M, Ko SJ, Kim CH et al. Reversible SUMOylation of TBL1-TBLR1 regulates beta-catenin-mediated Wnt signaling. Mol Cell 2011; 43: 203-216.
32. Perissi V, Scafoglio C, Zhang J, Ohgi KA, Rose DW, Glass CK et al. TBL1 and TBLR1 phosphorylation on regulated gene promoters overcomes dual CtBP and NCoR/ SMRT transcriptional repression checkpoints. Mol Cell 2008; 29: 755-766.
33. Oberoi J, Fairall L, Watson PJ, Yang JC, Czimmerer Z, Kampmann T et al. Structural basis for the assembly of the SMRT/NCoR core transcriptional repression machinery. Nat Struct Mol Biol 2011; 18: 177-184.
34. Ramadoss S, Li J, Ding X, Al Hezaimi K, Wang CY. Transducin beta-like protein recruits nuclear factor kappaB to the target gene promoter for transcriptional activation. Mol Cell Biol 2011; 31: 924-934.
35. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005; 105: 1768-1776.
36. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009; 114: 2733-2743.
37. Balusu R, Fiskus W, Rao R, Chong DG, Nalluri S, Mudunuru U et al. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood 2011; 118: 3096-3106.
38. Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther 2014; 13: 1142-1154.
39. Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SGT, Liu K et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia 2014; 28: 2155-2164.
40. Fiskus W, Saba N, Shen M, Ghias M, Das Gupta S, Chauhan L et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res 2014; 74: 2520-2532.
41. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174: 6477-6489.
42. Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, Swider CR et al. A robust xenotransplantation model for acute myeloid leukemia. Leukemia 2009; 23: 2109-2117.
43. Hoffmeyer K, Raggioli A, Rudloff S, Anton R, Hierholzer A, Del Valle I et al. Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells. Science 2012; 336: 1549-1554.
44. Zhang Y, Toh L, Lau P, Wang X. Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/beta-catenin pathway in human cancer. J Biol Chem 2012; 287: 32494-32511.
45. Siapati EK, Papadaki M, Kozaou Z, Rouka E, Michali E, Savvidou I et al. Proliferation and bone marrow engraftment of AML blasts is dependent on -catenin signalling. Br J Haematol 2011; 152: 164-174.
46. Abrahamsson AE, Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci 2009; 106: 3925-3929.
47. Goentoro L, Kirschner MW. Evidence that fold-change, and not absolute level, of beta-catenin dictates Wnt signaling. Mol Cell 2009; 36: 872-884.
48. Noubissi FK, Goswami S, Sanek NA, Kawakami K, Minamoto T, Moser A et al. Wnt signaling stimulates transcriptional outcome of the Hedgehog pathway by stabilizing GLI1 mRNA. Cancer Res 2009; 69: 8572-8578.
49. Rosenbluh J, Nijhawan D, Cox AJ, Li X, Neal JT, Schafer EJ et al. -Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 2012; 151: 1457-1473.
50. Shimizu T, Kagawa T, Inoue T, Nonaka A, Takada S, Aburatani H et al. Stabilized beta-catenin functions through TCF/LEF proteins and the Notch/RBP-Jkappa complex to promote proliferation and suppress differentiation of neural precursor cells. Mol Cell Biol 2008; 28: 7427-7441.
51. Tsai BP, Hoverter NP, Waterman ML. Blending hippo and WNT: sharing messengers and regulation. Cell 2012; 151: 1401-1403.
52. Skokowa J, Lan D, Thakur BK, Wang F, Gupta K, Cario G et al. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat Med 2009; 15: 151-158.
53. Tran T, Paz P, Velichko S, Cifrese J, Belur P, Yamaguchi KD et al. Interferon-1b induces the expression of RGS1 a negative regulator of G-protein signaling. Int J Cell Biol 2010; 2010: 529376.
54. Kode A, Manavalan JS, Mosialou I, Bhagat G, Rathinam CV, Luo N et al. Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts. Nature 2014; 506: 240-244.
55. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010; 6: 238-243.
56. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009; 114: 2984-2992.
57. Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK et al. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci USA 2014; 111: 5319-5324.